Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NEUROMETRIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

08/13/2021 | 08:00am EDT

Item 8.01. Other Events.

On August 13, 2021, NeuroMetrix, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") with the Securities and Exchange Commission (the "Commission") to register the offer and sale of $14,000,000 of the Company's common stock, par value $0.0001 per share (the "Common Stock") pursuant to the Company's effective "shelf" registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-229349) filed with the Commission on January 24, 2019, and declared effective on March 8, 2019 (together with the Prospectus Supplement, the "Prospectus"). The issuance and sale of the shares by the Company under the Prospectus will take place pursuant to the At Market Issuance Sales Agreement (the "Agreement"), dated February 19, 2020 between the Company and Ladenburg Thalmann & Co. Inc., under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock.

The legal opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, relating to the shares of Common Stock being offered pursuant to the Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

5.1       Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

10.1    At Market Issuance Sales Agreement, dated February 19, 2020, by and
        between NeuroMetrix, Inc. and Ladenburg Thalmann & Co. Inc. (filed as
        Exhibit 10.1 to the Registrant's Current Report on   Form 8-K   filed on
        February 19, 2020 and incorporated in this document by reference).

23.1      Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included
        in the opinion filed as Exhibit 5.1).

104     Cover Page Interactive Data File (embedded within the Inline XBRL


© Edgar Online, source Glimpses

All news about NEUROMETRIX, INC.
10/22NEUROMETRIX, INC. : Entry into a Material Definitive Agreement, Financial Statements and E..
10/21NEUROMETRIX : Management's Discussion and Analysis of Financial Condition and Results of O..
10/21NeuroMetrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
10/21NEUROMETRIX : Reports Q3 2021 Financial Results - Form 8-K
10/21NEUROMETRIX, INC. : Results of Operations and Financial Condition, Financial Statements an..
10/21NEUROMETRIX : Earnings Flash (NURO) NEUROMETRIX Reports Q3 Revenue $2.1M
10/21NeuroMetrix Reports Q3 2021 Financial Results
10/20NeuroMetrix, Inc. Names Susan M. Bell, RN, BN, as Senior Vice President of Population H..
10/14NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Ca..
10/07NeuroMetrix Shares Rise 10% After Submitting De Novo Request for Quell
More news